OKYO Pharma Limited(OKYO)Earnings, Financials & Key Ratios
OKYO•NASDAQ
$1.62
$66M mkt cap·Price updated May 7, 2026
AboutOKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.Show more
- Revenue$0
- EBITDA-$7M+54.2%
- Net Income-$5M+72.0%
- EPS (Diluted)-0.12-19900.0%
- Interest Coverage-8.14+45.4%
OKYO Key Insights
OKYO Pharma Limited (OKYO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 34.6% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
OKYO Price & Volume
OKYO Pharma Limited (OKYO) stock price & volume — 10-year historical chart
Loading chart...
OKYO Growth Metrics
OKYO Pharma Limited (OKYO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM18.13%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM0.08%
Return on Capital
10 Years-996.84%
5 Years-1077.89%
3 Years-2927.26%
Last Year-
OKYO Peer Comparison
OKYO Pharma Limited (OKYO) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 LNTH | 5.92B | 91.00 | 26.69 | 0.5% | 18.05% | 24.33% | 0.00 | |
 NVCR | 1.92B | 16.83 | -13.80 | 8.28% | -25.66% | -50.82% | 0.85 | |
 SGHT | 285.69M | 5.29 | -7.15 | -3.13% | -46.83% | -59.1% | 0.64 | |
 AVXL | 289.14M | 3.12 | -5.78 | -31.55% | ||||
 ALDX | 104.08M | 1.73 | -1.84 | -87.71% | 0.22 | |||
 HALO | 7.68B | 65.19 | 25.46 | 37.55% | 22.69% | 6.49% | ||
 TARS | 2.72B | 63.96 | -40.23 | 146.71% | -9.02% | -14.19% | 0.27 | |
 PRPH | 4.98M | 0.12 | -0.05 | -84.75% | -38.72% | -6.08% | 3.34 |
Compare OKYO vs Peers
OKYO Pharma Limited (OKYO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OKYO Income Statement
OKYO Pharma Limited (OKYO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 219 | 5.97K | 13.09K | 2.42K | 3.8K | 3.87K | 2.56K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | -219▲ 0% | -5.97K▼ 2626.5% | -13.09K▼ 119.2% | -2.42K▲ 81.5% | -3.8K▼ 56.7% | -3.87K▼ 1.8% | -2.56K▲ 33.7% |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | -2626.48% | -119.16% | 81.48% | -56.71% | -1.82% | 33.7% |
| Operating Expenses | 363.27K | 985.82K | 4.54M | 1.51M | 3.37M | 6.22M | 6.34M | 15.69M | 7.19M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 363.2K | 573.43K | 1.85M | 995.42K | 2.97M | 4.93M | 6.75M | 7.45M | 4.93M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 0 | 0 | 3.04M | 517.46K | 348.35K | 1.61M | 6.34M | 8.24M | 2.25M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | -12.43K | -15.81K | 0 | 43.65K | -320K | -6.75M | 0 | 0 |
| Operating Income | -363K▲ 0% | -28.29M▼ 7692.3% | -4.54M▲ 84.0% | -1.52M▲ 66.5% | -4.13M▼ 172.1% | -6.23M▼ 50.7% | -13.09M▼ 110.0% | -15.69M▼ 19.9% | -7.19M▲ 54.2% |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 67% | -7692.29% | 83.95% | 66.54% | -172.14% | -50.75% | -110.03% | -19.92% | 54.2% |
| EBITDA | -310.48K | 76.32M | -4.54M | -1.51M | -4.12M | -6.23M | -13.08M | -15.69M | -7.19M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 72.25% | 24680.65% | -105.95% | 66.67% | -172.34% | -51.17% | -110.05% | -19.93% | 54.2% |
| D&A (Non-Cash Add-back) | 52.52K | 104.61M | 218 | 5.97K | 13.11K | 2.33K | 3.8K | 3.87K | 2.56K |
| EBIT | -365K | 0 | -4.53M | -1.5M | -3.37M | -6.22M | -13.19M | -15.75M | -7.09M |
| Net Interest Income | 0 | 0 | 0 | 46.91K | -1.12K | 0 | -96.69K | -1.05M | -878.17K |
| Interest Income | 4.42K | 0 | 0 | 48.06K | 0 | 0 | 0 | 0 | 5.47K |
| Interest Expense | 0 | 0 | 0 | 1.16K | 1.12K | 0 | 96.69K | 1.05M | 883.65K |
| Other Income/Expense | 121.34K | -12.44K | -363K | -99.49K | 754.85K | 0 | -196.62K | -1.11M | -781.2K |
| Pretax Income | -242K▲ 0% | -28.27M▼ 11580.6% | -4.9M▲ 82.7% | -1.62M▲ 67.0% | -3.38M▼ 108.8% | -6.22M▼ 84.0% | -13.28M▼ 113.6% | -16.8M▼ 26.5% | -7.97M▲ 52.6% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | -76.19K | -24.99K | -787K | -12.2K | 22.41K | -3.26M |
| Effective Tax Rate % | 0% | 0% | 0% | 4.71% | 0.74% | 12.66% | 0.09% | -0.13% | 40.95% |
| Net Income | -243K▲ 0% | -28.3M▼ 11545.7% | -4.89M▲ 82.7% | -1.54M▲ 68.5% | -3.35M▼ 117.5% | -5.43M▼ 61.9% | -13.27M▼ 144.4% | -16.83M▼ 26.8% | -4.71M▲ 72.0% |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 70.37% | -11545.68% | 82.7% | 68.5% | -117.49% | -61.93% | -144.37% | -26.77% | 72.03% |
| Net Income (Continuing) | -242K | -28.27M | -4.9M | -1.54M | -3.35M | -5.43M | -13.27M | -16.83M | -4.71M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.04▲ 0% | -4.80▼ 11522.3% | -0.62▲ 87.1% | -0.17▲ 72.6% | -0.32▼ 88.2% | -0.36▼ 12.5% | -0.60▼ 66.7% | -0.00▲ 99.9% | -0.12▼ 19900.0% |
| EPS Growth % | 70.5% | -11522.28% | 87.08% | 72.58% | -88.24% | -12.5% | -66.67% | 99.9% | - |
| EPS (Basic) | -0.04 | -4.80 | -0.62 | -0.17 | -0.32 | -0.36 | -0.60 | -0.00 | -0.12 |
| Diluted Shares Outstanding | 5.86M | 5.89M | 7.91M | 9.16M | 10.35M | 15.06M | 22.26M | 29.34M | 39.49M |
| Basic Shares Outstanding | 5.86M | 5.89M | 7.91M | 9.16M | 10.35M | 15.06M | 22.26M | 29.34M | 39.49M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
OKYO Balance Sheet
OKYO Pharma Limited (OKYO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 16.86M | 48 | 758.75K | 566.73K | 6.99M | 4.3M | 5.2M | 1.54M | 3.68M |
| Cash & Short-Term Investments | 16.86M | 0 | 627.56K | 234.96K | 6.89M | 2.7M | 4.05M | 826.85K | 1.56M |
| Cash Only | 0 | 0 | 627.56K | 234.96K | 6.89M | 2.7M | 4.05M | 826.85K | 1.56M |
| Short-Term Investments | 16.86M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 48 | 111.36K | 326.22K | 4.5K | 883.43K | 980.08K | 580.94K | 1.89M |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 126 | -792 | 34 | -1.49K | 170.31K | 0 | 0 |
| Days Inventory Outstanding | - | - | 209.68 | - | 0.95 | - | 16.37K | - | - |
| Other Current Assets | 0 | 0 | 85.46K | 15 | 71.75K | 1.49K | -170.31K | 0 | 0 |
| Total Non-Current Assets | 0 | 0 | 1.1K | 30.66K | 104.64K | 5.22K | 7.22K | 3.35K | 2.04K |
| Property, Plant & Equipment | 0 | 0 | 1.1K | 30.66K | 104.64K | 5.22K | 7.22K | 3.35K | 2.04K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 0▲ 0% | 0▲ 0% | 759.86K▲ 0% | 597.4K▼ 21.4% | 7.09M▲ 1087.0% | 4.3M▼ 39.4% | 5.2M▲ 21.0% | 1.54M▼ 70.4% | 3.68M▲ 138.6% |
| Asset Turnover | - | - | - | - | - | - | - | - | - |
| Asset Growth % | -100% | - | - | -21.38% | 1087.03% | -39.35% | 21% | -70.38% | 138.59% |
| Total Current Liabilities | 0 | 0 | 426.72K | 710.66K | 1.71M | 1.35M | 7.26M | 7.42M | 9.23M |
| Accounts Payable | 141.79K | 0 | 381.76K | 593.72K | 210.99K | 517.67K | 1.02M | 6.13M | 7.9M |
| Days Payables Outstanding | - | - | 635.78K | 36.29K | 5.89K | 77.98K | 98.42K | 578.57K | 1000K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 34.14K | 0 | 2.22M | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 87.59K | -1.13K | -26.73K | 1.43M | 323.06K | 1.29M | 0 | 0 |
| Current Ratio | - | - | 1.78x | 0.80x | 4.09x | 3.17x | 0.72x | 0.21x | 0.40x |
| Quick Ratio | - | - | 1.78x | 0.80x | 4.09x | 3.18x | 0.69x | 0.21x | 0.40x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 26.54K | 64.61K | 0 | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 21.45K | 64.61K | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 5.08K | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 0 | 0 | 426.72K | 737.2K | 1.77M | 1.35M | 7.26M | 7.42M | 9.23M |
| Total Debt | 0 | 0 | 0 | 25.56K | 98.76K | 0 | 2.22M | 0 | 0 |
| Net Debt | 0 | 0 | -627.56K | -209.4K | -6.79M | -2.7M | -1.83M | -826.85K | -1.56M |
| Debt / Equity | - | - | - | - | 0.02x | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | -1313.88x | -3680.63x | - | -135.36x | -14.90x | -8.14x |
| Total Equity | 0▲ 0% | 0▲ 0% | 333.14K▲ 0% | -139.8K▼ 142.0% | 5.32M▲ 3905.0% | 2.95M▼ 44.6% | -2.05M▼ 169.7% | -5.88M▼ 186.4% | -5.55M▲ 5.6% |
| Equity Growth % | -100% | - | - | -141.96% | 3905.04% | -44.59% | -169.66% | -186.36% | 5.61% |
| Book Value per Share | - | - | 0.04 | -0.02 | 0.51 | 0.20 | -0.09 | -0.20 | -0.14 |
| Total Shareholders' Equity | 0 | 0 | 333.14K | -139.8K | 5.32M | 2.95M | -2.05M | -5.88M | -5.55M |
| Common Stock | 0 | 0 | 89.22M | 0 | 0 | 123.98M | 0 | 143.11M | 0 |
| Retained Earnings | 0 | 0 | -88.97M | -85.88M | -99.4M | -112.43M | -125.7M | -142.52M | -143.02M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 82.12K | 2.22M | 12.82M | -11.01M | -7.74M | -11.31M | -11.47M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OKYO Cash Flow Statement
OKYO Pharma Limited (OKYO) cash flow — operating, investing & free cash flow history
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -651.27K | -1.59M | -1.99M | -1.2M | -1.6M | -5.47M | -7.7M | -9.49M | -1.81M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -0.06% | -144.89% | -24.77% | 39.59% | -33.12% | -241.71% | -40.73% | -23.33% | 80.92% |
| Net Income | -241.93K | -28.27M | -4.9M | -1.62M | -3.38M | -6.22M | -13.28M | -16.83M | -7.97M |
| Depreciation & Amortization | 0 | 0 | 218 | 5.98K | 13.11K | 2.33K | 3.8K | 3.87K | 2.56K |
| Stock-Based Compensation | 18.37K | 4.24K | 50.53K | 36.34K | 544.39K | 1.72M | 1.27M | 1.12M | 734.99K |
| Deferred Taxes | 0 | 0 | -1.17K | 146.58K | 92.95K | -9.41K | 250.34K | 0 | 0 |
| Other Non-Cash Items | 0 | 26.63M | 2.69M | 42.84K | 83K | 61.72K | -84.16K | 3.54M | 1.8M |
| Working Capital Changes | -427.71K | 35.72K | 176.81K | 186.53K | 1.04M | -1.02M | 4.14M | 2.67M | 3.63M |
| Change in Receivables | 0 | 0 | 0 | -543 | 205.07K | 27.38K | 167.72K | 440.26K | -90.4K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | -297.99K | 0 | 2.8M | 0 |
| Cash from Investing | -375.39K | 0 | -1.32K | -132.67K | -18.11K | -1.67K | -5.92K | 0 | -1.21K |
| Capital Expenditures | -375.39K | 0 | -1.32K | 0 | -6.94K | -1.67K | -5.92K | 0 | -1.21K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -373.6K | 0 | 0 | -132.67K | -21 | 0 | 0 | 0 | 0 |
| Cash from Financing | 4.42K | 0 | 0 | 963.31K | 7.83M | 2.15M | 9.32M | 6.21M | 2.66M |
| Debt Issued (Net) | 4.42K | 0 | 0 | 0 | 7.58M | 0 | 2M | 0 | 950K |
| Equity Issued (Net) | 0 | 0 | 0 | 0 | 230.02K | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 963.31K | 15.87K | 725.51K | 0 | 0 | 0 |
| Net Change in Cash | -651.27K▲ 0% | -1.59M▼ 144.9% | -1.99M▼ 24.9% | -392.13K▲ 80.3% | 6.65M▲ 1796.8% | -4.19M▼ 163.0% | 1.34M▲ 132.1% | -3.22M▼ 339.4% | 734.05K▲ 122.8% |
| Free Cash Flow | -1.03M▲ 0% | -1.59M▼ 55.3% | -1.99M▼ 24.9% | -1.2M▲ 39.6% | -1.61M▼ 33.7% | -5.47M▼ 240.3% | -7.7M▼ 40.8% | -9.49M▼ 23.2% | -1.81M▲ 80.9% |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 2.86% | -55.35% | -24.85% | 39.63% | -33.7% | -240.34% | -40.8% | -23.24% | 80.91% |
| FCF per Share | -0.18 | -0.27 | -0.25 | -0.13 | -0.16 | -0.36 | -0.35 | -0.32 | -0.05 |
| FCF Conversion (FCF/Net Income) | 2.68x | 0.06x | 0.41x | 0.78x | 0.48x | 1.01x | 0.58x | 0.56x | 0.38x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OKYO Key Ratios
OKYO Pharma Limited (OKYO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -2.49% | - | - | -1469.36% | -1595.28% | -129.51% | -131.39% | -2968.58% | - | - |
| Return on Invested Capital (ROIC) | -3.04% | - | - | -17587.12% | - | - | -1894.47% | - | - | - |
| Debt / Equity | - | - | - | - | - | 0.02x | - | - | - | - |
| Interest Coverage | - | - | - | - | -1313.88x | -3680.63x | - | -135.36x | -14.90x | -8.14x |
| FCF Conversion | 0.79x | 2.68x | 0.06x | 0.41x | 0.78x | 0.48x | 1.01x | 0.58x | 0.56x | 0.38x |
OKYO Frequently Asked Questions
OKYO Pharma Limited (OKYO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
OKYO Pharma Limited (OKYO) grew revenue by 0.0% over the past year. Growth has been modest.
OKYO Pharma Limited (OKYO) reported a net loss of $4.7M for fiscal year 2025.
Dividend & Returns
OKYO Pharma Limited (OKYO) had negative free cash flow of $1.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More OKYO
OKYO Pharma Limited (OKYO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates